Clinical Trial Update: A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ultratrace Iobenguane I-131 in malignant relapsed/refractory pheochromocytoma and paraganglioma; results posted in 2018 but status is u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Ultratrace Iobenguane I-131 (iobenguane I-131)

Snippet

Sponsor: Molecular Insight Pharmaceuticals, Inc. | Conditions: Pheochromocytoma, Paraganglioma | Phase 2 | Status: UNKNOWN | Results posted: 2018-10-05